SCHEMBL2049342

SCHEMBL2049342

Cc1ncnc2c1ncn2[C@@H]1O[C@H](C)[C@H](O)[C@@H]1O

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 3/20 0.70
ADK P55263 3/20 0.53
SLC29A1 Q99808 2/20 0.52
AHCY P23526 3/20 0.50
ADORA2A P29274 2/20 0.50
ADORA2B P29275 2/20 0.50
DPP4 P27487 1/20 0.50
MEN1 O00255 1/20 0.50
SLC28A1 O00337 1/20 0.50
MAP3K7 O43318 1/20 0.50
SLC28A2 O43868 1/20 0.50
GAPDH P04406 1/20 0.50
MAPK1 P28482 1/20 0.50
ADORA1 P30542 1/20 0.50
STAT6 P42226 1/20 0.50
PI4KA P42356 1/20 0.50
KMT2A Q03164 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
PI4K2B Q8TCG2 1/20 0.50
DOT1L Q8TEK3 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2049339 1.00 ADORA3 (0.70) ADORA3ADKSLC29A1AHCYADORA2A
SCHEMBL2050691 1.00 ADORA3 (0.70) ADORA3ADKSLC29A1AHCYADORA2A
SCHEMBL8327426 0.86 ADORA3 (0.70) ADORA3ADKSLC29A1AHCYADORA2A
SCHEMBL8327434 0.86 ADORA3 (0.70) ADORA3ADKSLC29A1AHCYADORA2A
5'-Deoxyadenosine SCHEMBL14304623 0.85 AHCY (0.69) ADORA3SLC29A1AHCYADORA2AADORA2B
5'-Deoxyadenosine SCHEMBL542617 0.85 AHCY (0.69) ADORA3SLC29A1AHCYADORA2AADORA2B
5'-Deoxyadenosine SCHEMBL17677150 0.85 AHCY (0.69) ADORA3SLC29A1AHCYADORA2AADORA2B
5'-Deoxyadenosine SCHEMBL3459552 0.85 AHCY (0.69) ADORA3SLC29A1AHCYADORA2AADORA2B
SCHEMBL14264197 0.85 ADORA3 (0.69) ADORA3ADKSLC29A1AHCYADORA2A
5'-Deoxyadenosine SCHEMBL15926823 0.85 AHCY (0.69) ADORA3SLC29A1AHCYADORA2AADORA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1444335-A4 MUTANT PURINE NUCLEOSIDE PHOSPHORYLASE PROTEINS AND CELLULAR DELIVERY THEREOF UAB RESEARCH FOUNDATION (US) 2006-03-08 EP claimed
US-20050214901-A1 Mutant purine nucleoside phosphorylase proteins and cellular delivery thereof CORNELL CENTER FOR TECHNOLOGY, ENTERPRISE & COIMMERCIALIZATION 2005-09-29 US claimed
EP-1444335-A2 MUTANT PURINE NUCLEOSIDE PHOSPHORYLASE PROTEINS AND CELLULAR DELIVERY THEREOF UAB Research Foundation (US) 2004-08-11 EP claimed
WO-2003035012-A2 MUTANT PURINE NUCLEOSIDE PHOSPHORYLASE PROTEINS AND CELLULAR DELIVERY THEREOF UAB RESEARCH FOUNDATION (US) 2003-05-01 WO claimed
EP-2331115-B3 PURINE NUCLEOSIDE PHOSPHORYLASE AS ENZYMATIC ACTIVATOR OF NUCLEOSIDE PRODRUGS UAB RES FOUND (US) 2018-12-05 EP disclosed
EP-3150220-A1 PURINE NUCLEOSIDE PHOSPHORYLASE AS ENZYMATIC ACTIVATOR OF NUCLEOSIDE PRODRUGS The UAB Research Foundation (US) 2017-04-05 EP disclosed
EP-2331115-B1 PURINE NUCLEOSIDE PHOSPHORYLASE AS ENZYMATIC ACTIVATOR OF NUCLEOSIDE PRODRUGS UAB RESEARCH FOUNDATION (US) 2016-10-05 EP disclosed
US-20160022784-A1 PURINE NUCLEOSIDE PHOSPHORYLASE AS ENZYMATIC ACTIVATOR OF NUCLEOSIDE PRODRUGS CORNELL UNIVERSITY 2016-01-28 US disclosed
US-20140199285-A1 PURINE NUCLEOSIDE PHOSPHORYLASE AS ENZYMATIC ACTIVATOR OF NUCLEOSIDE PRODRUGS SOUTHERN RESEARCH INSTITUTE (US) 2014-07-17 US disclosed
US-20110212073-A1 PURINE NUCLEOSIDE PHOSPHORYLASE AS ENZYMATIC ACTIVATOR OF NUCLEOSIDE PRODRUGS THE UAB RESEARCH FOUNDATION (US) 2011-09-01 US disclosed
EP-2331115-A2 PURINE NUCLEOSIDE PHOSPHORYLASE AS ENZYMATIC ACTIVATOR OF NUCLEOSIDE PRODRUGS The UAB Research Foundation (US) 2011-06-15 EP disclosed
WO-2010019954-A9 PURINE NUCLEOSIDE PHOSPHORYLASE AS ENZYMATIC ACTIVATOR OF NUCLEOSIDE PRODRUGS THE UAB RESEARCH FOUNDATION (US) 2010-08-12 WO disclosed
WO-2010019954-A2 PURINE NUCLEOSIDE PHOSPHORYLASE AS ENZYMATIC ACTIVATOR OF NUCLEOSIDE PRODRUGS THE UAB RESEARCH FOUNDATION (US) 2010-02-18 WO disclosed
US-7488598-B2 Mutant purine nucleoside phosphorylase proteins and cellular delivery thereof CORNELL CENTER FOR TECHNOLOGY ENTERPRISE AND COMMERCIALIZATION (US) 2009-02-10 US disclosed
US-20050214901-A1 Mutant purine nucleoside phosphorylase proteins and cellular delivery thereof CORNELL CENTER FOR TECHNOLOGY, ENTERPRISE & COIMMERCIALIZATION 2005-09-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050214901-A1 Mutant purine nucleoside phosphorylase proteins and cellular delivery thereof PNP, UPP1, TYMP ADORA3 974/4885ADK 209/4885SLC29A1 50/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.